Search
Acetarsol
go.drugbank.com/drugs/DB13268ApprovedWithdrawnAcetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties. … [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964.
Maraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Diosmin
go.drugbank.com/drugs/DB08995ApprovedInvestigationalChronic venous insufficiency is a common condition the western population. … Diosmin is widely available over-the-counter and demonstrates a favourable a favorable safety profile.[A232890,T840,L33040]
Mixtures: NATurmeric
go.drugbank.com/drugs/DB14276ApprovedInvestigationalTurmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Yu JinRevefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigationalThe labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions. … Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA).
Marstacimab
go.drugbank.com/drugs/DB17725ApprovedInvestigational[L51803] It is a tissue factor pathway inhibitor (TFPI) antagonist, which is an endogenous anticoagulant. … [A264608] Marstacimab is used to prevent bleeding episodes in patients with hemophilia,[L51803] which is an X‐linked bleeding disorder characterized by coagulation clotting factor deficiency.
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[A264199] Upon administration, PTH is cleaved from palopegteriparatide in a controlled manner to achieve a continuous systemic exposure of active PTH. … Palopegteriparatide is a parathyroid hormone (PTH) analog.
Synonyms: Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isole, Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34Propoxycaine
go.drugbank.com/drugs/DB09342ApprovedPropoxycaine is a local anesthetic of the ester type that has a rapid onset of action and a longer duration of action than procaine hydrochloride [L1588]. … Used in combination with procaine, it was the only dental local anesthetic available in cartridge form [L1592].
Oxilofrine
go.drugbank.com/drugs/DB11610ApprovedOxilofrine is used in combination with [DB11609] as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.
Tasonermin
go.drugbank.com/drugs/DB11626ApprovedIt was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma … It is administered with [DB01042] via mild hyperthermic isolated limb perfusion.